EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Chromosomal Microarray Analysis in 466 Patients With Autism Spectrum Disorder: Diagnostic Yield and Clinical Correlates

Giulia Borini, Chiara Davico, Lisa Pavinato, Emanuela Nobile, Erika Borroz, Simona Cardaropoli, Roberta Marinoni, Eleonora Di Gregorio, Valentina Francesca Cudia, Daniele Marcotulli, Barbara Pasini, Alessandro Mussa, Roberto Keller, Giovanni Battista Ferrero, Alfredo Brusco, Diana Carli

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · 2026-11-05

DOI: 10.1002/ajmg.b.70043 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Autism spectrum disorder (ASD) has a strong genetic component. Chromosomal microarray analysis is recommended as a first‐tier genetic test for individuals with ASD, with a reported diagnostic yield of 5.4%–14%. We performed a‐CGH analysis in ASD patients to evaluate diagnostic yield and genotype–phenotype correlations. Clinical features were collected and analyzed to assess associations with pathogenic/likely pathogenic (P/LP) CNVs. Segregation analysis was performed when feasible. A total of 466 patients were included (22.1% female; age range 3–59 years). Twenty‐two patients (4.7%) carried at least one P/LP CNV, 129 (27.7%) had a variant of uncertain significance (VUS), and 315 (67.6%) tested negative. No significant associations were observed between a positive a‐CGH result and age, family history, autism severity, perinatal distress, epilepsy, intellectual disability, congenital malformations, micro‐/macrocephaly, or facial dysmorphisms. In contrast, positivity was significantly higher in females ( p = 0.029) and in individuals with growth disorders ( p = 0.003). a‐CGH showed a diagnostic yield of 4.7%, slightly below the lower range reported in the literature. Clinically significant CNVs were also identified in individuals with isolated ASD, supporting the use of a‐CGH beyond syndromic presentations. Overall, a‐CGH analysis in ASD plays a dual role: identifying established risk loci and uncovering emerging candidate genes.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →